Graphite Bio gives up on lead sickle cell program, halves staff in wake of safety scare
It took a little more than a month for Graphite Bio to conclude that there’s no way out of the safety issues unearthed in the first clinical trial of its first gene editing program. Not now.
Having paused a Phase I/II trial in the beginning of 2023 after the first patient to receive the product developed a serious side effect, Graphite says it’s shelving the program, nulabeglogene autogedtemcel, and kicking off a process to explore strategic alternatives — something that often results in a sale, reverse merger or even wind-down these days.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.